近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L; Meikle SR; Gregoire MC; Rye KA, 2016, 'In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes', Diabetologia, vol. 59, no. 9, pp. 1977 - 1984, http://dx.doi.org/10.1007/s00125-016-3993-5 Geronimo FRB; Barter PJ; Rye KA; Heather AK; Shearston KD; Rodgers KJ, 2016, 'Plaque stabilizing effects of apolipoprotein A-IV', Atherosclerosis, vol. 251, pp. 39 - 46, http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.019 Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJG; Yamashita S, 2016, 'Defining severe familial hypercholesterolaemia and the implications for clinical management: A consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia P', The Lancet Diabetes and Endocrinology, http://dx.doi.org/10.1016/S2213-8587(16)30041-9 Sultana A; Cochran BJ; Tabet F; Patel M; Torres LC; Barter PJ; Rye KA, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', The FASEB Journal, vol. 30, no. 6, pp. 2324 - 2335, http://dx.doi.org/10.1096/fj.201500026R Tabet F; Torres LFC; Ong KL; Shrestha S; Choteau SA; Barter PJ; Clifton P; Rye KA, 2016, 'High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males', PLoS One, vol. 11, no. 3, http://dx.doi.org/10.1371/journal.pone.0151061 Barter PJ; Rye KA, 2016, 'Coronary artery disease: Scavenger receptor class B1-a target to reduce CHD risk?', Nature Reviews Cardiology, vol. 13, no. 5, pp. 249 - 250, http://dx.doi.org/10.1038/nrcardio.2016.50 Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia', American Journal of Cardiology, vol. 117, no. 9, pp. 1444 - 1448, http://dx.doi.org/10.1016/j.amjcard.2016.02.011 Barter PJ; Rye KA, 2016, 'New era of lipid-lowering drugs', Pharmacological Reviews, vol. 68, no. 2, pp. 458 - 475, http://dx.doi.org/10.1124/pr.115.012203 Barter PJ; Rye KA, 2016, 'Cholesteryl ester transfer protein inhibition is not yet dead - Pro', Arteriosclerosis, Thrombosis and Vascular Biology, vol. 36, no. 3, pp. 439 - 441, http://dx.doi.org/10.1161/ATVBAHA.115.306879 Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Hu B; Uno K; Kataoka Y; Herrman JPR; Merkely B; Borgman M; Nissen SE, 2016, 'Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial', American Journal of Cardiovascular Drugs, vol. 16, no. 1, pp. 55 - 65, http://dx.doi.org/10.1007/s40256-015-0146-z Barter PJ; Rye KA, 2016, 'Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro', Arteriosclerosis, Thrombosis and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.115.306879 Puranik R; Bao S; Bonin AM; Kaur R; Weder JE; Casbolt L; Hambley TW; Lay PA; Barter PJ; Rye KA, 2016, 'A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo', Cell and Bioscience, vol. 6, no. 1, http://dx.doi.org/10.1186/s13578-016-0076-8 Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Hu B; Uno K; Kataoka Y; Herrman J-PR; Merkely B; Borgman M; Nissen SE, 2016, 'Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial', American Journal of Cardiovascular Drugs, vol. 16, no. 1, pp. 55 - 65, http://dx.doi.org/10.1007/s40256-015-0146-z Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis', European Journal of Preventive Cardiology, vol. 23, no. 7, pp. 744 - 747, http://dx.doi.org/10.1177/2047487315598710 Barter PJ; Rye KA, 2015, 'Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?', Clinical Therapeutics: the international peer-reviewed journal of drug therapy, vol. 37, no. 12, pp. 2716 - 2731, http://dx.doi.org/10.1016/j.clinthera.2015.07.021 Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Riesmeyer J; Vangerow B; Ruotolo G; Weerakkody GJ; Nissen SE, 2015, 'Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial', American Heart Journal, vol. 170, no. 6, pp. 1061 - 1069, http://dx.doi.org/10.1016/j.ahj.2015.09.007 Rye KA; Barter PJ; Cochran BJ, 2015, 'Apolipoprotein A-I interactions with insulin secretion and production', Current Opinion in Lipidology, http://dx.doi.org/10.1097/MOL.0000000000000253 Rye KA; Barter PJ; Brown AJ, 2015, 'Speed kills in more ways than one: Methamphetamine and atherosclerosis', Atherosclerosis, vol. 243, no. 2, pp. 654 - 655, http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.034 Barter PJ; Tabet F; Rye KA, 2015, 'Reduction in PCSK9 levels induced by anacetrapib: An off-target effect?', Journal of Lipid Research, vol. 56, no. 11, pp. 2085 - 2093, http://dx.doi.org/10.1194/jlr.C063768 Bisoendial R; Tabet F; Tak PP; Petrides F; Cuesta Torres LF; Hou L; Cook A; Barter P; Weninger W; Rye KA, 2015, 'Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis', Arteriosclerosis, Thrombosis and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.115.305777